Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Flex Pharma Presenting at Upcoming Investor Conferences in September 2016

Business Wire September 1, 2016

Flex Pharma Announces Scientific Advisory Board Appointment and Management Change

Business Wire August 26, 2016

Flex Pharma Reports Second Quarter 2016 Financial Results

Business Wire August 3, 2016

Flex Pharma to Report Second Quarter 2016 Results on August 3, 2016

Business Wire July 27, 2016

Flex Pharma Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps

Business Wire July 26, 2016

Flex Pharma to Present at the Cantor Fitzgerald Healthcare Conference

Business Wire July 6, 2016

Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis

Business Wire June 15, 2016

Flex Pharma Presenting at Upcoming Investor Conferences in June 2016

Business Wire June 3, 2016

Scientific Breakthrough In Sports Nutrition To Change The Game For Millions Of Endurance Athletes

PR Newswire June 2, 2016

Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps

Business Wire June 2, 2016

Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps

Business Wire May 25, 2016

Flex Pharma Reports First Quarter 2016 Financial Results

Business Wire May 4, 2016

Flex Pharma to Report First Quarter 2016 Results on May 4, 2016

Business Wire April 27, 2016

Flex Pharma's Positive Human NLC Study Selected for Presentation at AAN Annual Meeting

Business Wire April 19, 2016

Flex Pharma Collaborator Penn State Presents Positive Human Muscle Cramp Data

Business Wire April 6, 2016

Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting

Business Wire March 14, 2016

Flex Pharma Reports Year End 2015 Financial Results

Business Wire March 8, 2016

Michelle V. Stacy Joins Flex Pharma's Board of Directors

Business Wire March 7, 2016

Flex Pharma to Report Full Year 2015 Results on March 8, 2016

Business Wire March 1, 2016

Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study

Business Wire February 2, 2016